Apogenix AG:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Apogenix AG - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C0468
◆発行会社(調査会社):GlobalData
◆発行日:2018年7月
◆ページ数:20
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ドイツ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Apogenix AG (Apogenix) is a developer of immuno-oncology medicines for the treatment of oncological and malignant hematological diseases. The company’s pipeline drug candidates under clinical development include APG101, a CD95 ligand inhibitor for the treatment of glioblastoma and myelodysplastic syndromes. Apogenix has developed the proprietary HERA technology platform for the construction of novel hexavalent receptor agonists for the treatment of cancer. It also conducts preclinical and clinical studies for various tumor indications. The company partners with other pharmaceutical and biotechnology companies and collaborates with academic institutions for the preclinical, clinical development and commercialization of its proprietary drug candidates. Apogenix is headquartered Heidelberg, Germany.

Apogenix AG – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Apogenix AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Apogenix AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Apogenix AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Apogenix AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Apogenix AG, Medical Devices Deals, 2012 to YTD 2018 9
Apogenix AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Apogenix AG, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Apogenix Secures US$9.8 Million In Venture Financing 11
Licensing Agreements 12
CANbridge Life Sciences Extends Licensing Agreement with Apogenix 12
AbbVie Enters into Licensing Agreement with Apogenix 13
Apogenix AG – Key Competitors 14
Apogenix AG – Key Employees 15
Apogenix AG – Locations And Subsidiaries 16
Head Office 16
Recent Developments 17
Product News 17
Sep 13, 2017: CrownBio’s Integrated Oncology Platform Helps Advance Apogenix’s Promising HERA-GITRL Immunotherapy for NSCLC and Head and Neck Cancer 17
Mar 20, 2017: Apogenix Presents Data on Novel Hexavalent TNF Receptor Agonists (HERA) at the Upcoming Annual Meeting of the American Association for Cancer Research (AACR) 18
Appendix 20
Methodology 20
About GlobalData 20
Contact Us 20
Disclaimer 20

List of Tables
Apogenix AG, Pharmaceuticals & Healthcare, Key Facts 2
Apogenix AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Apogenix AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Apogenix AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Apogenix AG, Deals By Therapy Area, 2012 to YTD 2018 8
Apogenix AG, Medical Devices Deals, 2012 to YTD 2018 9
Apogenix AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Apogenix Secures US$9.8 Million In Venture Financing 11
CANbridge Life Sciences Extends Licensing Agreement with Apogenix 12
AbbVie Enters into Licensing Agreement with Apogenix 13
Apogenix AG, Key Competitors 14
Apogenix AG, Key Employees 15

List of Figures
Apogenix AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Apogenix AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Apogenix AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Apogenix AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Apogenix AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Apogenix AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Apogenix AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Apogenix AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Apogenix AG, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Apogenix AG:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Evgen Pharma Plc (EVG):製薬・医療:M&Aディール及び事業提携情報
    Summary Evgen Pharma Plc (Evgen Pharma), formerly Evgen Pharma Ltd is a clinical-stage drug development company that develops clinical pipeline for breast cancer and subarachnoid haemorrhage. The company develops SFX-01 to reduce the vasospasm and incidence of delayed cerebral ischemia which leads t …
  • DiamondRock Hospitality Co:企業のM&A・事業提携・投資動向
    DiamondRock Hospitality Co - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's DiamondRock Hospitality Co Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acqui …
  • Croda International Plc (CRDA):企業の財務・戦略的SWOT分析
    Croda International Plc (CRDA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Ambrx Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Ambrx Inc (Ambrx) is a biopharmaceutical company that offers discovery and development of protein-based medicines by using its expanded genetic code. The company provides pipeline product candidate’s portfolio such as ARX618 FGF21, PSMA ADC, CD70 ADC and Anti-CD3 X Folate. It develops pipeli …
  • Koninklijke Vopak NV (VPK):企業の財務・戦略的SWOT分析
    Koninklijke Vopak NV (VPK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Kuraray Co., Ltd.:企業の戦略・SWOT・財務分析
    Kuraray Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Kuraray Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Univision Communications Inc.:企業の戦略的SWOT分析
    Univision Communications Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Peace River Electric Cooperative, Inc.:発電所・企業SWOT分析
    Peace River Electric Cooperative, Inc. - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, informati …
  • International Finance Corp:企業の戦略的SWOT分析
    International Finance Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Hog’s Breath Cafe (Australia) Pty Ltd:企業の戦略・SWOT・財務情報
    Hog's Breath Cafe (Australia) Pty Ltd - Strategy, SWOT and Corporate Finance Report Summary Hog's Breath Cafe (Australia) Pty Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • Essel Propack Limited:戦略・SWOT・企業財務分析
    Essel Propack Limited - Strategy, SWOT and Corporate Finance Report Summary Essel Propack Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • The Netherlands Cancer Institute-製薬・医療分野:企業M&A・提携分析
    Summary The Netherlands Cancer Institute (NCI) is a research institute that offers cancer research and treatment services. The institute conducts research in the areas of cell biology, diagnostic oncology, medical oncology, molecular carcinogenesis, biochemistry, biological stress response, gene reg …
  • M+W Group GmbH:企業の戦略・SWOT・財務情報
    M+W Group GmbH - Strategy, SWOT and Corporate Finance Report Summary M+W Group GmbH - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Glori Energy Inc:石油・ガス:M&Aディール及び事業提携情報
    Summary Glori Energy Inc (Glori Energy) is an energy technology and an oil production company. The company deploys proprietary technology to increase the amount of oil that can be produced from conventional oil fields which it marketed to third party exploration and production companies. It also own …
  • Stentys SA (STNT):医療機器:M&Aディール及び事業提携情報
    Summary Stentys SA (Stentys) is a medical device company that designs, develops and markets self-expanding stents for the treatment of patients with acute myocardial infarction and coronary disease. The company’s products include xposition S self-applying stent, mistent biodegradable sirolimus relea …
  • Dentsu, Inc.:企業の戦略・SWOT・財務情報
    Dentsu, Inc. - Strategy, SWOT and Corporate Finance Report Summary Dentsu, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Blueberry Therapeutics Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Blueberry Therapeutics Ltd (Blueberry Therapeutics) is a healthcare products provider that develops therapeutic products. The company develops novel therapies to treat onychomycosis. Its pipeline product portfolio includes BB2603-NCE, developed to treat onychomycosis and associated tinea ped …
  • BiondVax Pharmaceuticals Ltd (BVXV):企業の財務・戦略的SWOT分析
    Summary BiondVax Pharmaceuticals Ltd (BiondVax Pharmaceuticals) is a biopharmaceutical company that develops universal flu vaccine. The company provides lead product M-001 is a synthetic peptide-based protein that offers protection against human influenza virus strains including seasonal influenza s …
  • Sage Therapeutics Inc (SAGE):製薬・医療:M&Aディール及び事業提携情報
    Summary Sage Therapeutics Inc (Sage) is a clinical-stage biopharmaceutical company that discovers and develops therapeutics and medicines for central nervous system (CNS) disorders. It develops drugs based on selective allosteric modulation of CNS synaptic and extrasynaptic receptors. The company ha …
  • Oryzon Genomics SA (ORY):企業の財務・戦略的SWOT分析
    Summary Oryzon Genomics SA (Oryzon) is a clinical-stage biopharmaceutical company that offers discovers and develops epigenetic therapies to treat oncology and neurodegenerative diseases. The company offers epigenetics, a regulatory system that controls gene expression without affecting the makeup o …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆